Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): A randomised, open-label, multicentre, phase 2 trial

The Lancet Oncology

Volumn 16, Issue 16, 2015, Pages 1700-1710

  Cortés, Javier ^a,t   Dieras, Véronique ^b   Ro, Jungsil ^c   Barriere, Jérôme ^d   Bachelot, Thomas ^e   Hurvitz, Sara ^f   Le Rhun, Emilie ^g,h   Espié, Marc ⁱ   Kim, Sung Bae ^j   Schneeweiss, Andreas ^k   Sohn, Joo Hyuk ^l   Nabholtz, Jean Marc ^m   Kellokumpu Lehtinen, Pirkko Liisa ⁿ   Taguchi, Julie ^o   Piacentini, Federico ^p   Ciruelos, Eva ^q   Bono, Petri ^r   Ould Kaci, Mahmoud ^s   Roux, Flavien ^s   Joensuu, Heikki ^r  

^a VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^b INSTITUT CURIE   (France)

^c National Cancer Center   (South Korea)

^d CENTRE ANTOINE LACASSAGNE   (France)

^e CENTRE LÉON BÉRARD   (France)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g CENTRE OSCAR LAMBRET   (France)

^h LILLE UNIVERSITY HOSPITAL   (France)

ⁱ SAINT LOUIS HOSPITAL   (France)

^j University of Ulsan College of Medicine   (South Korea)

^k UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^l Yonsei University College of Medicine   (South Korea)

^m CENTRE JEAN PERRIN   (France)

ⁿ TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^o Sansum Clinic   (United States)

^p UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^q HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^r HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^s BOEHRINGER INGELHEIM   (France)

^t HOSPITAL RAMÓN Y CAJAL   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; NAVELBINE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; TUMOR MARKER; VINBLASTINE;

ACUTE KIDNEY FAILURE; ADULT; ANEMIA; ARTICLE; ASTHENIA; BRAIN METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DYSPHAGIA; ENTERITIS; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOCAL EPILEPSY; HUMAN; LUNG INFECTION; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; STOMATITIS; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; UROSEPSIS; VOMITING; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CANADA; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; EUROPE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SECONDARY; SOUTH KOREA; TIME FACTOR; UNITED STATES;

ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; BREAST NEOPLASMS; CANADA; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; EUROPE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, ERBB-2; REPUBLIC OF KOREA; RISK FACTORS; TIME FACTORS; TRASTUZUMAB; TREATMENT OUTCOME; UNITED STATES; VINBLASTINE;

EID: 84948808453     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00373-3     Document Type: Article

References (30)

1. Ramakrishna N, Temin S, Chandarlapaty S, et al. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2014, 32:2100-2108.
2. Gori S, Rimondini S, De Angelis V, et al. Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors. Oncologist 2007, 12:766-773.
3. Melisko ME, Moore DH, Sneed PK, De Franco J, Rugo HS Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival. J Neurooncol 2008, 88:359-365.
4. Eichler AF, Kuter I, Ryan P, Schapira L, Younger J, Henson JW Survival in patients with brain metastases from breast cancer: the importance of HER-2 status. Cancer 2008, 112:2359-2367.
5. Bachelot T, Romieu G, Campone M, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol 2013, 14:64-71.
6. Lin NU, Carey LA, Liu MC, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008, 26:1993-1999.
7. Lin NU, Dieras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009, 15:1452-1459.
8. Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008, 27:4702-4711.
9. Lin NU, Winer EP, Wheatley D, et al. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res Treat 2012, 133:1057-1065.
10. Bahleda R, Soria J, Berge Y, et al. Phase I trial assessing safety and pharmacokinetics of afatinib (BIBW 2992) with intravenous weekly vinorelbine in advanced solid tumors. J Clin Oncol 2011, 29(suppl):2585. (abstr).
11. Mukai H, Masuda N, Ishiguro H, et al. Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors including breast cancer. Cancer Chemother Pharmacol 2015, 76:739-750.
12. Harbeck N, Huang C-S, Hurvitz SA, et al. Randomized phase III trial of afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one prior trastuzumab treatment: LUX-Breast 1. Cancer Res 2015, 75. P5-19-01 (abstr).
13. Yang JC, Shih JY, Su WC, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol 2012, 13:539-548.
14. Solca F, Dahl G, Zoephel A, et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 2012, 343:342-350.
15. Simon R, Wittes RE, Ellenberg SS Randomized phase II clinical trials. Cancer Treat Rep 1985, 69:1375-1381.
16. von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26/breast international group 03-05 study. J Clin Oncol 2009, 27:1999-2006.
17. von Minckwitz G, Schwedler K, Schmidt M, et al. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer 2011, 47:2273-2281.
18. Blackwell KL, Burstein HJ, Storniolo AM, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol 2012, 30:2585-2592.
19. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355:2733-2743.
20. Krop IE, Kim SB, Gonzalez-Martin A, et al. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol 2014, 15:689-699.
21. Mehta AI, Brufsky AM, Sampson JH Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier. Cancer Treat Rev 2013, 39:261-269.
22. Lin NU, Eierman W, Greil R, et al. Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. J Neurooncol 2011, 105:613-620.
23. Stemmler HJ, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 2007, 18:23-28.
24. Dijkers EC, Oude Munnink TH, Kosterink JG, et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 2010, 87:586-592.
25. Polli JW, Humphreys JE, Harmon KA, et al. The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos 2008, 36:695-701.
26. Lin NU, Bellon JR, Winer EP CNS metastases in breast cancer. J Clin Oncol 2004, 22:3608-3617.
27. Tomasello G, Bedard PL, de Azambuja E, Lossignol D, Devriendt D, Piccart-Gebhart MJ Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib. Crit Rev Oncol Hematol 2010, 75:110-121.
28. Leyland-Jones B Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol 2009, 27:5278-5286.
29. Schuler M, Yang JC, Sequist LV, et al. Efficacy of afatinib vs chemotherapy in treatment-naive patients with non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations with or without metastatic brain disease. J Thorac Oncol 2013, 8(suppl 2):S299. (abstr MO07.13).
30. Hoffknecht P, Tufman A, Wehler T, et al. Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease. J Thorac Oncol 2015, 10:156-163.